ZA952433B - Recombinant viruses their preparation and their use in gene therapy - Google Patents

Recombinant viruses their preparation and their use in gene therapy

Info

Publication number
ZA952433B
ZA952433B ZA952433A ZA952433A ZA952433B ZA 952433 B ZA952433 B ZA 952433B ZA 952433 A ZA952433 A ZA 952433A ZA 952433 A ZA952433 A ZA 952433A ZA 952433 B ZA952433 B ZA 952433B
Authority
ZA
South Africa
Prior art keywords
gdnf
adenovirus
cell
dna sequence
recombinant
Prior art date
Application number
ZA952433A
Other languages
English (en)
Inventor
Phlippe Horellou
Jacques Mallet
Michel Perricaudet
Frederic Revah
Emmanuelle Vigne
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of ZA952433B publication Critical patent/ZA952433B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA952433A 1994-03-25 1995-03-24 Recombinant viruses their preparation and their use in gene therapy ZA952433B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9403542A FR2717824B1 (fr) 1994-03-25 1994-03-25 Virus recombinants, préparation et utilisation en thérapie génique.

Publications (1)

Publication Number Publication Date
ZA952433B true ZA952433B (en) 1996-01-15

Family

ID=9461438

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA952433A ZA952433B (en) 1994-03-25 1995-03-24 Recombinant viruses their preparation and their use in gene therapy

Country Status (14)

Country Link
US (1) US6245330B1 (de)
EP (1) EP0752004B1 (de)
JP (1) JPH09510620A (de)
KR (1) KR100403707B1 (de)
AT (1) ATE335832T1 (de)
AU (1) AU704910B2 (de)
CA (1) CA2184841C (de)
DE (1) DE69535155T2 (de)
FI (1) FI963805A0 (de)
FR (1) FR2717824B1 (de)
IL (1) IL113109A0 (de)
MX (1) MX9604024A (de)
WO (1) WO1995026408A1 (de)
ZA (1) ZA952433B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008026A1 (en) * 1992-09-25 1994-04-14 Rhone-Poulenc Rorer S.A. Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system, particularly in brain
US20020031493A1 (en) * 1994-03-25 2002-03-14 Rhone-Poulenc Rorer S.A. Recombinant adenoviruses coding for glial-derived cell neurotrophic factor (gdnf)
US5733875A (en) * 1994-11-15 1998-03-31 Amgen Inc. Methods of using GDNF as a neuroprotective agent
US5731284A (en) * 1995-09-28 1998-03-24 Amgen Inc. Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
US6184200B1 (en) * 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
US5929041A (en) * 1996-02-23 1999-07-27 Amgen Inc. Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product
US5837681A (en) * 1996-02-23 1998-11-17 Amgen Inc. Method for treating sensorineural hearing loss using glial cell line-derived neurotrophic factor (GDNF) protein product
US5741778A (en) * 1996-03-19 1998-04-21 Amgen Inc. Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
FR2753379B1 (fr) * 1996-09-13 1998-10-30 Rhone Poulenc Rorer Sa Methode de traitement de la sclerose laterale amyotrophique
WO1998046737A2 (en) * 1997-04-15 1998-10-22 University Of Medicine And Dentistry Of New Jersey cDNA FOR HUMAN GDNF AND PROMOTER THEREFOR WHICH ALLOWS REGULATED AND CONSTITUTIVE EXPRESSION
US6043221A (en) 1997-07-30 2000-03-28 Amgen Inc. Method for preventing and treating hearing loss using a neuturin protein product
US6277820B1 (en) 1998-04-09 2001-08-21 Genentech, Inc. Method of dopaminergic and serotonergic neuron formation from neuroprogenitor cells
DE19816186A1 (de) * 1998-04-14 1999-10-21 Univ Muenchen L Maximilians GDNF-kodierende DNA, Teile davon und GDNF-Varianten
IL146694A (en) 2001-11-22 2010-12-30 Biomas Ltd Use of an aqueous solution containing a biologically active complex of tellurium dioxide for manufacturing a medicament
WO2003055983A2 (en) * 2001-12-21 2003-07-10 The Salk Institute For Biological Studies Targeted retrograde gene delivery to motor neurons
EP1694313A4 (de) * 2003-12-18 2010-11-17 Biomas Ltd Tellurium-derivate für die prävention und behandlung von neurodegenerativen prozessen
BRPI0710800A2 (pt) 2006-04-25 2012-01-17 Univ California administração de fatores de crescimento para o tratamento de distúrbios de snc
JP2009535360A (ja) * 2006-04-26 2009-10-01 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 高分子量神経治療薬の対流増加送達のための組成物および方法
WO2008154644A1 (en) 2007-06-12 2008-12-18 Case Western Reserve University Targeted cell death
MX2010012592A (es) 2008-05-20 2011-05-05 Eos Neuroscience Inc Vectores para la administracion de proteinas sensibles a la luz y metodos de uso de las mismas.
US20140259192A1 (en) 2011-07-12 2014-09-11 Sanofi Transgenic animal comprising a deletion or functional deletion of the 3'utr of an endogenous gene
WO2014152511A1 (en) 2013-03-15 2014-09-25 The Jackson Laboratory Methods for promoting wound healing and hair growth
WO2019174697A1 (en) 2018-03-15 2019-09-19 Coloplast A/S Apparatus and methods for navigating ostomy appliance user to changing room

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
FR2688514A1 (fr) * 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
WO1994008026A1 (en) * 1992-09-25 1994-04-14 Rhone-Poulenc Rorer S.A. Adenovirus vectors for the transfer of foreign genes into cells of the central nervous system, particularly in brain
FR2702152B1 (fr) * 1993-03-03 1995-05-24 Inst Nat Sante Rech Med Virus recombinants et leur utilisation en thérapie génique.

Also Published As

Publication number Publication date
FR2717824A1 (fr) 1995-09-29
EP0752004B1 (de) 2006-08-09
DE69535155T2 (de) 2007-06-28
AU2141195A (en) 1995-10-17
DE69535155D1 (de) 2006-09-21
JPH09510620A (ja) 1997-10-28
WO1995026408A1 (fr) 1995-10-05
CA2184841A1 (fr) 1995-10-05
KR100403707B1 (ko) 2004-02-11
EP0752004A1 (de) 1997-01-08
FI963805A (fi) 1996-09-24
FI963805A0 (fi) 1996-09-24
MX9604024A (es) 1997-09-30
US6245330B1 (en) 2001-06-12
ATE335832T1 (de) 2006-09-15
FR2717824B1 (fr) 1996-04-26
CA2184841C (fr) 2009-08-18
KR970702373A (ko) 1997-05-13
IL113109A0 (en) 1995-06-29
AU704910B2 (en) 1999-05-06

Similar Documents

Publication Publication Date Title
ZA952433B (en) Recombinant viruses their preparation and their use in gene therapy
AU712775B2 (en) Adenoviral-vector-mediated gene transfer into medullary motor neurons
Barkats et al. Adenovirus in the brain: recent advances of gene therapy for neurodegenerative diseases
Oligino et al. Vector systems for gene transfer to joints.
Akimoto et al. Adenovirally expressed basic fibroblast growth factor rescues photoreceptor cells in RCS rats.
Haase et al. Adenovirus-mediated transfer of the neurotrophin-3 gene into skeletal muscle of pmn mice: therapeutic effects and mechanisms of action
US6685934B1 (en) Recombinant adenoviruses coding for basic fibroblast growth factors (BFGF)
KR20060045056A (ko) 릴랙신 유전자를 포함하는 유전자 전달 시스템 및 릴랙신을이용한 약제학적 조성물
EP1674108A3 (de) Behandlung von Osteoporose
Horellou et al. Gene therapy for Parkinson's disease
Horellou et al. Adenovirus-mediated gene transfer to the central nervous system for Parkinson's disease
Sauer et al. Brain-derived neurotrophic factor and neurotrophin-45 modify neurotransmitter-related gene expression in the 6-hydroxydopamine-lesioned rat striatum
Robert et al. Adenovirus-mediated transfer of a functional GAD gene into nerve cells: potential for the treatment of neurological diseases
AU2002364221A1 (en) Targeted retrograde gene delivery to motor neurons
Chiocco et al. Neurotrophic factors for the treatment of Parkinson's disease
CN1155706C (zh) 肌萎缩性侧索硬化的治疗方法
AU7154698A (en) Ngf variants
EP0969875B1 (de) Gen-einführung in mark-motoneuronen mittels eines nackten dnas
Horellou et al. In VivoAdenovirus-Mediated Gene Transfer for Parkinson's Disease
Kojima et al. Construction and Characterization of Adenoviral Vector Expressing Biologically-Active Brain-Derived Neurotrophic Factor
Yamano et al. Prospects for gene-based immunopharmacology in salivary glands
DiStefano et al. Regulation of Schwann cell surface and truncated nerve growth factor receptors in vitro by axonal components
AU703793B2 (en) Recombinant adenoviruses coding for brain-derived neurotrophic factor (BDNF)
EP4025258A1 (de) Verfahren und zusammensetzungen zur behandlung von als
US20050069523A1 (en) Recombinant adenoviruses encoding glial cell neurotrophic factor (GDNF)